Cancer Immunotherapy Biomarkers — CHD1/MAP3K7 Deletion Insights

Cancer immunotherapy biomarkers and CHD1/MAP3K7 deletion in predicting immunotherapy response New insights into dual-gene deletion, tumor response to immunotherapy, and emerging immunotherapy success predictors Understand how CHD1 and MAP3K7 co-deletion could guide personalized cancer treatment and precision oncology decisions What You'll Learn: How CHD1 and MAP3K7 co-deletion functions as a potential cancer immunotherapy biomarker to predict which patients may benefit most from treatment Why CHD1+MAP3K7 co-deletion appears in roughly 8% of primary and 15% of metastatic prostate tumors, and how that prevalence shapes clinical and research priorities What preclinical mouse data reveal about a 5-fold increase in CD8+ T-cell infiltration and a 6-fold rise in STING pathway transcripts in dual-deleted tumors How a Johns Hopkins pembrolizumab cohort (n=57) showed a 33% objective response rate in dual-deleted tumors versus 7% in non-deleted tumors, and why this signal still requires independent validation Practical ways these findings could inform biomarker development, patient stratification, and immunotherapy trial design in prostate cancer and other solid tumors How CHD1/MAP3K7 deletion research integrates with existing biomarkers for cancer treatment, including PD-L1, MSI, and TMB, in predicting immunotherapy response Key methodological and translational challenges that must be addressed before CHD1/MAP3K7 co-deletion can be used as a routine immunotherapy success predictor in the clinic